Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli

Blood (2023) 142 (Supplement 1): 654.

https://doi.org/10.1182/blood-2023-172590

Published: 2023

Journal Articles

The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

Norbert Hollaender, Ekkehard Glimm, Jennifer Gauvin, Tommaso Stefanelli, Robert Zeiser

Blood (2022) 140 (Supplement 1): 10521–10522.

https://doi.org/10.1182/blood-2022-159432

Published: 2022

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima

Blood (2021) 138 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2021-144576

Published: 2021

Journal Articles

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, PhD, Nicola Polverelli, MD PhD, Ron Ram, MD, Shahrukh K. Hashmi, MDMPH, Ronjon Chakraverty, BMBS, PhD, Mary E. D. Flowers, MD, Fitzroy Dawkins, MD, Norbert Hollaender, MD, Maanasa Gowda, PharmD, Tommaso Stefanelli, MD, Stephanie J. Lee, MDMPH, Takanori Teshima, MD, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 22–24.

https://doi.org/10.1182/blood-2020-137694

Published: 2020

Journal Articles

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Udvardy Miklos, Vladimir Strugov, MD, Catharina Lewerin, MD PhD, Sebastian Grosicki, MD PhD, Grzegorz Mazur, MD PhD, Michael Steurer, MD, Marco Montillo, MD, Irina Kryachok, Prof., PhD, Jan Moritz Middeke, MD, Grygoriy Rekhtman, MD, Tommaso Stefanelli, Ghislaine Vincent, Sameera G, PhD, Anders Österborg, MD PhD Prof.

Blood (2018) 132 (Supplement 1): 5569.

https://doi.org/10.1182/blood-2018-99-113295

Published: 2018

Journal Articles

Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial

Sebastian Grosicki, MD PhD, Ewa Lech-Maranda, MD PhD, K Govind Babu, MD DM, Justyna Rybka, MD PhD, Elena Litvinskaya, PhD, Javier Loscertales, MD, Irina Kryachok, Prof., PhD, Janusz Kłoczko, Prof., PhD, Grygoriy Rekhtman, MD, Wojciech Homenda, MD PhD, Jerzy Blonski, MD PhD, Tommaso Stefanelli, Ghislaine Vincent, Hiya Banerjee, Tadeusz Robak, MD PhD

Blood (2018) 132 (Supplement 1): 3151.

https://doi.org/10.1182/blood-2018-99-112139

Published: 2018

NARROW

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial

Email alerts

ASH Publications

American Society of Hematology

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only